|
|
 Previous Article | Table of Contents | Next Article 
High-dose therapy and autologous peripheral blood stem cell transplantation
for patients with lymphoma
A Kessinger, JO Armitage, DM Smith, JD Landmark, PJ Bierman and DD Weisenburger
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha 68105.
Forty patients with refractory Hodgkin's disease (24 patients) or non-
Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy
but not for autologous bone marrow transplantation (ABMT) due to BM
metastases, previous pelvic irradiation, a history of marrow involvement by
tumor or hypocellular marrow in conventional harvest sites received
high-dose therapy and autologous peripheral blood (PB) hematopoietic stem
cell transplantation. Disappearance of circulating neutrophils and
development of RBC and platelet transfusion-dependence was followed, in the
evaluable patients, by reappearance of 0.5 x 10(9)/L circulating
granulocytes and sufficient platelets to obviate the need for platelet
transfusions at a median of 25 days after transplantation. Twenty-three
patients experienced a clinical complete remission (CR). The projected
2-year event-free survival was 24% for all 40 patients and 49% for the
non-Hodgkin's lymphoma patients. The projected 18-month event-free survival
for the Hodgkin's disease patients was 15%. PB stem cell transplantation
provided an opportunity to administer high-dose salvage therapy to patients
with refractory lymphoma who otherwise were not candidates for such
therapy. For some of those patients, the high-dose therapy produced
prolonged survival, free of tumor progression.
Volume 74,
Issue 4,
pp. 1260-1265,
09/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Betticher, G Martinelli, J. Radford, M Kaufmann, M. Dyer, U Kaiser, W. Aulitzky, J Beck, A von Rohr, T Kovascovics, et al.
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
Ann. Onc.,
October 1, 2006;
17(10):
1546 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fukuda, K. Shimada, A. Tanaka, T. Kawarabayashi, M. Yoshiyama, and J. Yoshikawa
Circulating monocytes and in-stent neointima after coronary stent implantation
J. Am. Coll. Cardiol.,
January 7, 2004;
43(1):
18 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S L Preston, M R Alison, S J Forbes, N C Direkze, R Poulsom, and N A Wright
The new stem cell biology: something for everyone
Mol. Pathol.,
April 1, 2003;
56(2):
86 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, G. Sharp, W. C. Chan, C. Nichols, K. Loh, D. Inwards, R. Rifkin, P. J. Bierman, J. C. Lynch, D. D. Weisenburger, et al.
Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease
J. Clin. Oncol.,
May 1, 2002;
20(9):
2344 - 2352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Fontes and A. W Thomson
Stem cell technology
BMJ,
November 13, 1999;
319(7220):
1308 - 1308.
[Full Text]
|
|
|
|
|
|
|
A. K.W. Lie and L. B. To
Peripheral Blood Stem Cells: Transplantation and Beyond
Oncologist,
February 1, 1997;
2(1):
40 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. DeVita and S. M. Hubbard
Hodgkin's Disease
N. Engl. J. Med.,
February 25, 1993;
328(8):
560 - 565.
[Full Text]
|
|
|
|
|
|
|
M Gabbianelli, M Sargiacomo, E Pelosi, U Testa, G Isacchi, and C Peschle
"Pure" human hematopoietic progenitors: permissive action of basic fibroblast growth factor
Science,
September 28, 1990;
249(4976):
1561 - 1564.
[Abstract]
[PDF]
|
|
|
|
|
